Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Patient's own immune cells be engineered to fight a rare sarcoma?

NCT ID NCT07104682

Cure Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial tests a personalized cell therapy called GCAR1 in a single patient with metastatic alveolar soft part sarcoma (ASPS) that has relapsed and cannot be surgically removed. The therapy uses the patient's own immune cells, engineered to recognize and attack cancer cells displaying a specific protein. The goal is to see if this treatment is safe and can shrink or control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GCAR1, a personalized cell therapy made from the patient's own immune cells (T-cells) engineered to recognize and attack cancer cells that carry a protein called GPNMB.
What this could lead to
If successful, this approach could offer a new treatment option for alveolar soft part sarcoma, a rare cancer with limited therapies.
What could go wrong
This is an early, single-patient study, so results may not apply to others. CAR T-cell therapy can cause severe side effects, and the treatment may not shrink the tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 1 person

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have relapsed ASPS that is in the opinion of the treating physician not resectable, or that resection would be associated with significant morbidity. * The patient must provide informed consent. * The only other eligibility criteria is adequate organ function, defined as creatinine clearance \>30 ml/min and LVEF \>45%. Exclusion Criteria: * Any active uncontrolled infection * Any anti-cancer therapy within 21 calendar days prior to the first dose of lymphodepleting chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar soft part sarcoma (ASPS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alveolar soft part sarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alveolar soft part sarcoma (ASPS) Sarcoma

Contacts and locations

Locations

  • University of Calgary

    Calgary, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.